CMMB — Chemomab Therapeutics Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapNeutral
- $1.14m
- -$31.56m
- 13
- 59
- 43
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.04 | ||
| Price to Tang. Book | 0.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -115.16% | ||
| Return on Equity | -73.47% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Directors
- Stephen Squinto NEC (64)
- Adi Mor CEO (40)
- Donald Marvin CFO (69)
- Aaron Aharon OTH (52)
- Neil Cohen IND (57)
- Nissim Darvish IND (56)
- Joel Maryles IND (61)
- Alan Moses IND (73)
- Claude Nicaise IND (68)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- September 22nd, 2011
- Public Since
- August 14th, 2012
- No. of Shareholders
- 7
- No. of Employees
- 37
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 14,539,793.75
- Address
- Kiryat Atidim, Building 7, TEL AVIV-YAFO, 6158002
- Web
- https://www.chemomab.com/
- Phone
- +972 25486555
- Contact
- Irina Koffler
- Auditors
- Somekh Chaikin
Upcoming Events for CMMB
Q3 2023 Chemomab Therapeutics Ltd Earnings Release
Similar to CMMB
180 Life Sciences
NASDAQ Capital Market
9 Meters Biopharma
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Aceragen
NASDAQ Capital Market
FAQ
What is the Chemomab Therapeutics share price?
As of Today at 19:04 UTC, shares in Chemomab Therapeutics are trading at $1.57. This share price information is delayed by 15 minutes.
How has the Chemomab Therapeutics share price performed this year?
Shares in Chemomab Therapeutics last closed at $1.57 and the price had moved by -49.03% over the past 365 days. In terms of relative price strength the Chemomab Therapeutics share price has underperformed the S&P500 Index by -49.98% over the past year.
What are the analyst and broker recommendations for Chemomab Therapeutics?
The overall consensus recommendation for Chemomab Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Chemomab Therapeutics dividend yield?
Chemomab Therapeutics does not currently pay a dividend.
Does Chemomab Therapeutics pay a dividend?
Chemomab Therapeutics does not currently pay a dividend.
When does Chemomab Therapeutics next pay dividends?
Chemomab Therapeutics does not currently pay a dividend.
How do I buy Chemomab Therapeutics shares?
To buy shares in Chemomab Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Chemomab Therapeutics?
As of the previous close price of $1.57, shares in Chemomab Therapeutics had a market capitalisation of $1.14m.
Where are Chemomab Therapeutics shares listed?
Here are the trading details for Chemomab Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CMMB
What kind of share is Chemomab Therapeutics?
Based on an overall assessment of its quality, value and momentum Chemomab Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Chemomab Therapeutics share price forecast for 2023?
The analyst consensus target price for shares in Chemomab Therapeutics is $293.40. That is 18587.9% above the last closing price of $1.57.
Analysts covering Chemomab Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.08 for the next financial year.
What is the trend in the Chemomab Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chemomab Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -31.73%.
As of the last closing price of $1.57, shares in Chemomab Therapeutics were trading -26.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Chemomab Therapeutics PE Ratio?
The Chemomab Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Chemomab Therapeutics?
Chemomab Therapeutics' management team is headed by:
- Stephen Squinto - NEC
- Adi Mor - CEO
- Donald Marvin - CFO
- Aaron Aharon - OTH
- Neil Cohen - IND
- Nissim Darvish - IND
- Joel Maryles - IND
- Alan Moses - IND
- Claude Nicaise - IND